Inhibikase Therapeutics (IKT) Retained Earnings (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly Retained Earnings of -$159.1 million for Q1 2026, down 16448776.94% year-over-year from N/an in Q1 2025, and down 11.48% quarter-over-quarter from -$142.7 million in Q4 2025.
Inhibikase Therapeutics (IKT) Retained Earnings (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Retained Earnings for 7 consecutive years, with -$159.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 16448776.94% year-over-year to -$159.1 million; the TTM figure through Mar 2026 stood at -$159.1 million (down 16448776.94% YoY), while the FY2025 annual figure was -$142.7 million, down 51.11% from the prior year.
- Retained Earnings fell to -$159.1 million in Q1 2026 per IKT's latest filing, from -$142.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at $165822.0 in Q1 2023 and bottomed at -$159.1 million in Q1 2026.
- Historically, Retained Earnings has averaged -$35.8 million across 5 years, with a median of -$2944.0 in 2025.
- Annual changes were most pronounced in 2023 — Retained Earnings soared 100.48% — and 2026, when it tumbled 16448776.94%.
- Inhibikase Therapeutics' Retained Earnings stood at $104718.0 in 2022, then tumbled by 99.16% to $877.0 in 2023, then plunged by 10766418.24% to -$94.4 million in 2024, then slumped by 51.11% to -$142.7 million in 2025, then decreased by 11.48% to -$159.1 million in 2026.
- Business Quant data shows IKT's Retained Earnings at -$159.1 million in Q1 2026, -$142.7 million in Q4 2025, and -$4189.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | -178.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -178.70 Mn |
| Mar 31, 2026 | -159.06 Mn |
| Dec 31, 2025 | -142.68 Mn |
| Sep 30, 2025 | -4,189.00 |
| Jun 30, 2025 | -2,944.00 |
| Mar 31, 2025 | -967.00 |
| Dec 31, 2024 | -94.42 Mn |
| Sep 30, 2024 | 1,754.00 |
| Jun 30, 2024 | -76.51 Mn |
| Mar 31, 2024 | -1,800.00 |
| Dec 31, 2023 | 877.00 |
| Sep 30, 2023 | -62.72 Mn |
| Jun 30, 2023 | -1,714.00 |
| Mar 31, 2023 | 165,822.00 |
| Dec 31, 2022 | 104,718.00 |
| Sep 30, 2022 | 26,828.00 |
| Jun 30, 2022 | -39.10 Mn |
| Mar 31, 2022 | -34.46 Mn |
| Dec 31, 2021 | -29.82 Mn |
| Sep 30, 2021 | -24.78 Mn |